NasdaqGS:MMEDMedical Equipment
MiniMed Study Highlights Algorithm Strength And Raises Questions On Depressed Valuation
MiniMed Group (NasdaqGS:MMED) released peer reviewed clinical data showing its insulin pump algorithm maintains consistent glycemic outcomes across different glucose sensors.
The study is backed by extensive real world evidence, covering thousands of patients using MiniMed’s automated insulin delivery platform.
Findings point to the algorithm as the main driver of glycemic control, rather than the specific sensor paired with the pump.
MiniMed Group, trading at $11.18, is drawing attention...